iShares Biotechnology ETF
624 hedge funds and large institutions have $5.69B invested in iShares Biotechnology ETF in 2017 Q4 according to their latest regulatory filings, with 124 funds opening new positions, 207 increasing their positions, 192 reducing their positions, and 77 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
624
Holders Change
+41
Holders Change %
+7.03%
% of All Funds
14.17%
Holding in Top 10
30
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.68%
New
124
Increased
207
Reduced
192
Closed
77
Calls
$533M
Puts
$1.25B
Net Calls
-$712M
Net Calls Change
-$479M
Top Buyers
| 1 |
UBS Group
Zurich,
Switzerland
|
+$114M |
| 2 |
Citigroup
New York
|
+$57.4M |
| 3 |
Two Sigma Advisers
New York
|
+$31.4M |
| 4 |
Two Sigma Investments
New York
|
+$26.2M |
| 5 |
ACI
AMP Capital Investors
Sydney,
Australia
|
+$25.6M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$169M |
| 2 |
Goldman Sachs
New York
|
-$139M |
| 3 |
N
Natixis
Paris,
France
|
-$95.3M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$81.7M |
| 5 |
JPMorgan Chase & Co
New York
|
-$70.6M |